HIGHER SURVIVAL OF REFRACTORY METASTATIZING BREAST-CANCER AFTER THERMOTHERAPY AND AUTOLOGOUS SPECIFIC ANTITUMORAL IMMUNOTHERAPY

46 women (average 54.3 yrs) with refractory metastatizing breast cance r were treated with thermotherapy and autologous specific immunotherap y (rhIL-2 ex vivo activated cells). Metastases involved one organ in 6 9%; in particular; bone, lung, liver: The PS after treatment was satis factory in 41%; the outcome was better in those cases with metastases to one site, The women remaining alive were 31/46; 67% of thermo-immun otherapy treated patients were alive after a maximum survival time of 85 months (median 24 months). The 36 months of control showed a 5-fold higher survival rate in our series when challenged with that of compa red women undergoing only chemotherapy (p<.001).